Sequence and functional analysis of the envelope glycoproteins of hepatitis C virus variants selectively transmitted to a new host

Journal of Virology

Volumn 87, Issue 24, 2013, Pages 13609-13618

  D'Arienzo, Valentina ^a   Moreau, Alain ^a   D'Alteroche, Louis ^a,b   Gissot, Valérie ^a   Blanchard, Emmanuelle ^a   Gaudy Graffin, Catherine ^a,c   Roch, Emmanuelle ^a   Dubois, Frédéric ^c   Giraudeau, Bruno ^a   Plantier, Jean Christophe ^d   Goudeau, Alain ^a,c   Roingeard, Philippe ^a   Brand, Denys ^a,c  

^a UNIVERSITÉ DE TOURS   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c CHU BRETONNEAU   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ARTICLE; CASE REPORT; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; NEEDLESTICK INJURY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIREMIA; VIRUS ENTRY; VIRUS MUTANT; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

AMINO ACID SEQUENCE; ANIMALS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MICE; MOLECULAR SEQUENCE DATA; PHYLOGENY; SEQUENCE ALIGNMENT; VIRAL ENVELOPE PROTEINS;

EID: 84888070513     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02119-13     Document Type: Article

References (56)

1. WHO. 2013. Hepatitis C. WHO fact sheet 164. WHO, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs164/en/index.html.
2. Ascione A, Tartaglione MT, Di Costanzo GG. 2007. Natural history of chronic hepatitis C virus infection. Dig. Liver Dis. 39(Suppl 1):S4-S7.
3. Maheshwari A, Ray S, Thuluvath PJ. 2008. Acute hepatitis C. Lancet 372:321-332.
4. Averhoff FM, Glass N, Holtzman D. 2012. Global burden of hepatitis C:considerations for healthcare providers in the United States. Clin. Infect. Dis. 55(Suppl 1):S10-S5.
5. Yazdanpanah Y, De Carli G, Migueres B, Lot F, Campins M, Colombo C, Thomas T, Deuffic-Burban S, Prevot MH, Domart M, Tarantola A, Abiteboul D, Deny P, Pol S, Desenclos JC, Puro V, Bouvet E. 2005. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure:a European case-control study. Clin. Infect. Dis. 41:1423-1430.
6. Morin T, Pariente A, Lahmek P, Investigator Group of ANGHSPILFFNPRH. 2011. Favorable outcome of acute occupational hepatitis C in healthcare workers:a multicenter French study on 23 cases. Eur. J. Gastroenterol. Hepatol. 23:515-520.
7. Liu CH, Chen BF, Chen SC, Lai MY, Kao JH, Chen DS. 2006. Selective transmission of hepatitis C virus quasi species through a needlestick accident in acute resolving hepatitis. Clin. Infect. Dis. 42:1254-1259.
8. Saito T, Watanabe H, Shao L, Okumoto K, Hattori E, Sanjo M, Misawa K, Suzuki A, Takeda T, Sugahara K, Ito JI, Saito K, Togashi H, Kawata S. 2004. Transmission of hepatitis C virus quasispecies between human adults. Hepatol. Res. 30:57-62.
9. Moradpour D, Penin F, Rice CM. 2007. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5:453-463.
10. Bull RA, Luciani F, McElroy K, Gaudieri S, Pham ST, Chopra A, Cameron B, Maher L, Dore GJ, White PA, Lloyd AR. 2011. Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog. 7:e1002243. doi:10.1371/journal.ppat.1002243.
11. Wang GP, Sherrill-Mix SA, Chang KM, Quince C, Bushman FD. 2010. HepatitisCvirus transmission bottlenecks analyzed by deep sequencing. J. Virol. 84:6218-6228.
12. Li H, Stoddard MB, Wang S, Blair LM, Giorgi EE, Parrish EH, Learn GH, Hraber P, Goepfert PA, Saag MS, Denny TN, Haynes BF, Hahn BH, Ribeiro RM, Perelson AS, Korber BT, Bhattacharya T, Shaw GM. 2012. Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog. 8:e1002880. doi:10.1371/journal.ppat.1002880.
13. Brown RJ, Hudson N, Wilson G, Rehman SU, Jabbari S, Hu K, Tarr AW, Borrow P, Joyce M, Lewis J, Zhu LF, Law M, Kneteman N, Tyrrell DL, McKeating JA, Ball JK. 2012. Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. J. Virol. 86:11956-11966.
14. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U.S.A. 105:7552-7557.
15. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5:molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28:2731-2739.
16. Korber B, Myers G. 1992. Signature pattern analysis:a method for assessing viral sequence relatedness. AIDS Res. Hum. Retroviruses 8:1549-1560.
17. Crooks GE, Hon G, Chandonia JM, Brenner SE. 2004. WebLogo:a sequence logo generator. Genome Res. 14:1188-1190.
18. Connor RI, Chen BK, Choe S, Landau NR. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944.
19. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA. 2003. Hepatitis C virus glycoproteins mediate pHdependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U.S.A. 100:7271-7276.
20. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottom A, Levy S, McKeating JA. 1999. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 73:6235-6244.
21. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14:25-27.
22. Keck ZY, Li TK, Xia J, Gal-Tanamy M, Olson O, Li SH, Patel AH, Ball JK, Lemon SM, Foung SK. 2008. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J. Virol. 82:6061-6066.
23. Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, Leroux-Roels G, Patel AH, Cosset FL, Pessaux P, Doffoël M, Wolf P, Stoll-Keller F, Baumert TF. 2010. Viral entry and escape from antibodymediated neutralization influence hepatitis C virus reinfection in liver transplantation. J. Exp. Med. 207:2019-2031.
24. Sugitani M, Shikata T. 1998. Comparison of amino acid sequences in hypervariable region-1 of hepatitis C virus clones between human inocula and the infected chimpanzee sera. Virus Res. 56:177-182.
25. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH, Parrish NF, Shaw KS, Guffey MB, Bar KJ, Davis KL, Ochsenbauer-Jambor C, Kappes JC, Saag MS, Cohen MS, Mulenga J, Derdeyn CA, Allen S, Hunter E, Markowitz M, Hraber P, Perelson AS, Bhattacharya T, Haynes BF, Korber BT, Hahn BH, Shaw GM. 2009. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206:1273-1289.
26. Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, Haim H, Petersen JE, Wojcechowskyj JA, Sodroski J, Haynes BF, Montefiori DC, Tilton JC, Shaw GM, Hahn BH, Doms RW. 2011. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J. Virol. 85:8514-8527.
27. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West AP, Bjorkman PJ, Wilen CB, Doms RW, O'Brien M, Bhardwaj N, Borrow P, Haynes BF, Muldoon M, Theiler JP, Korber B, Shaw GM, Hahn BH. 2013. Phenotypic properties of transmitted founder HIV-1. Proc. Natl. Acad. Sci. U.S.A. 110:6626-6633.
28. Ray SC, Fanning L, Wang XH, Netski DM, Kenny-Walsh E, Thomas DL. 2005. Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J. Exp. Med. 201:1753-1759.
29. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21:5017-5025.
30. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL. 2005. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J. Virol. 79:8217-8229.
31. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL. 2003. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278:41624-41630.
32. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. 2009. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 136:2377-2386.
33. Guan M, Wang W, Liu X, Tong Y, Liu Y, Ren H, Zhu S, Dubuisson J, Baumert TF, Zhu Y, Peng H, Aurelian L, Zhao P, Qi Z. 2012. Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J. Biol. Chem. 287:35631-35645.
34. Callens N, Ciczora Y, Bartosch B, Vu-Dac N, Cosset FL, Pawlotsky JM, Penin F, Dubuisson J. 2005. Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein E2 contribute to virus entry. J. Virol. 79:15331-15341.
35. Penin F, Combet C, Germanidis G, Frainais PO, Deléage G, Pawlotsky JM. 2001. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J. Virol. 75:5703-5710.
36. Owsianka AM, Timms JM, Tarr AW, Brown RJP, Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH, Ball JK. 2006. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitisCvirus that are critical for CD81 binding. J. Virol. 80:8695-8704.
37. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, Dubuisson J. 2005. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 79:8400-8409.
38. Boo I, te Wierik K, Douam F, Lavillette D, Poumbourios P, Drummer HE. 2012. Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidine residues of hepatitis C virus glycoprotein E1 and E2. Biochem. J. 443:85-94.
39. Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, Foung SK, Penin F, Dubuisson J, Voisset C. 2007. The neutralizing activity of anti-hepatitisCvirus antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. 81:8101-8111.
40. Meredith LW, Wilson GK, Fletcher NF, McKeating JA. 2012. Hepatitis C virus entry:beyond receptors. Rev. Med. Virol. 22:182-193.
41. Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T. 2012. Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology 56:484-491.
42. Owen DM, Huang H, Ye J, Gale M, Jr. 2009. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with lowdensity lipoprotein receptor. Virology 394:99-108.
43. Mazumdar B, Banerjee A, Meyer K, Ray R. 2011. Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. Hepatology 54:1149-1156.
44. Popescu CI, Dubuisson J. 2010. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol. Cell 102:63-74.
45. Kawaguchi K, Faulk K, Purcell RH, Emerson SU. 2011. Reproduction in vitro of a quasispecies from a hepatitis C virus-infected patient and determination of factors that influence selection of a dominant species. J. Virol. 85:3408-3414.
46. Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J. 2009. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems:role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49:364-377.
47. Bartosch B, Dubuisson J, Cosset FL. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:633-642.
48. Haberstroh A, Schnober EK, Zeisel MB, Carolla P, Barth H, Blum HE, Cosset FL, Koutsoudakis G, Bartenschlager R, Union A, Depla E, Owsianka A, Patel AH, Schuster C, Stoll-Keller F, Doffoël M, Dreux M, Baumert TF. 2008. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology 135:1719-1728.
49. Fofana I, Kremer SF, Carolla P, Fauvelle C, Zahid MN, Turek M, Heydmann L, Cury K, Hayer J, Combet C, Cosset FL, Pietschmann T, Hiet MS, Bartenschlager R, Habersetzer F, Doffoël M, Keck ZY, Foung SK, Zeisel MB, Stoll-Keller F, Baumert TF. 2012. Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 143:223-233.
50. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, McKeating JA. 2007. Hepatitis C virus continuously escapes from neutralizing antibody and T-Cell responses during chronic infection in vivo. Gastroenterology 132:667-678.
51. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M. 2012. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 109:6205-6210.
52. Keck ZY, Xia J, Wang Y, Wang W, Krey T, Prentoe J, Carlsen T, Li AY, Patel AH, Lemon SM, Bukh J, Rey FA, Foung SK. 2012. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog. 8:e1002653. doi:10.1371/journal.ppat.1002653.
53. Edwards VC, Tarr AW, Urbanowicz RA, Ball JK. 2012. The role of neutralizing antibodies in hepatitis C virus infection. J. Gen. Virol. 93:1-19.
54. Meunier JC, Russell RS, Goossens V, Priem S, Walter H, Depla E, Union A, Faulk KN, Bukh J, Emerson SU, Purcell RH. 2008. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J. Virol. 82:966-973.
55. Meuleman P, Bukh J, Verhoye L, Farhoudi A, Vanwolleghem T, Wang RY, Desombere I, Alter H, Purcell RH, Leroux-Roels G. 2011. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 53:755-762.
56. Yu MW, Bartosch B, Zhang P, Guo Z, Renzi PM, Shen L, Granier C, Feinstone SM, Cosset FL, Purcell RH. 2004. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCVpositive plasma. Proc. Natl. Acad. Sci. U.S.A. 101:7705-7710.